ESR1 and breast cancer: In conclusion, the novel hERG activators, SDUY429 and SDUY436, have demonstrated significant inhibitory efficacy on the proliferation, migration and invasion of breast cancer cells, including TNBC-derived MDA-MB-231 and ER+-derived MCF-7 cells.